Signal Royalty Partners
Signal Defense Royalties acquires IP-backed revenue streams from mid-market defense tech companies. Government-backed cash flows. No equity dilution. First-mover advantage.
Learn MoreThe Opportunity
FY2027 defense budget request. 42% increase over current levels.
Manufacturing-focused defense investment in 2025. Up 81% year over year.
Dedicated defense royalty platforms. We're building the first.
Defense tech companies create critical IP through SBIR grants, R&D contracts, and proprietary innovation. Their options to monetize that IP are limited: sell the company, raise dilutive equity, or let it sit. Signal offers a better path.
Process
Step 01
Patents, production rights, or contract-backed revenue streams from DoD or prime contractor relationships.
Step 02
We acquire a share of future licensing fees, production royalties, or contract-derived cash flows. Typically $5-50M per transaction.
Step 03
No board seats. No dilution. Non-dilutive capital that lets founders and operators stay in control.
Criteria
Advantage
Healthcare has Royalty Pharma. Entertainment has IP licensing platforms. Defense has nothing purpose-built. We're creating the category.
Proprietary infrastructure monitors SBIR awards, federal contracts, defense patents, and company financials 24/7. We find opportunities before traditional BD teams.
Signal Royalty Partners operates the same model in healthcare. Same operator-led underwriting. Same structured approach. Defense is the next vertical.
Contact
If you're a defense technology company with valuable IP, or an investor interested in government-backed cash flows, we'd like to hear from you.
sam@signalroyalties.com